An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice

Roche

Status: Completed

Conditions: Lymphoma, B-Cell, Lymphoma, Follicular

Study type: Observational

Funder types: Industry

Identifiers

NCT02240316

ML28886

Details and patient eligibility

About

This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) or previously untreated CD-20 positive diffuse large B-cell lymphoma (DLBCL) who are planned for therapy with MabThera SC according to the assessment of the physician will be prospectively enrolled for observation. No study specific measures are required; treatment and documentation will be performed according to usual clinical practice.

Enrollment: 688 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women and men aged >=18 years
• Previously untreated CD-20 positive follicular NHL
• Previously untreated CD-20 positive DLBCL
• Planned therapy with MabThera SC according to the assessment of the physician (before the start and independent from this study)
• Suitability for the therapy with MabThera SC

Exclusion criteria

All contraindications, interactions and incompatibilities for therapy with MabThera SC

Trial design

688 participants in 2 patient groups

Follicular NHL Cohort

DLBCL Cohort